PRODUCTS & SERVICES
Project title: Novel, precise and early diagnostics of pancreatic neuroendocrine tumors using miRNA signatures
Funding Scheme: The Ministry of Health of the Slovak Republic (ONKO)
Duration in months: 36
Estimated budget: 384 469,00 EUR
Our project is focused on the development and pre-clinical validation of novel, precise and early diagnostics of pancreatic neuroendocrine tumors (pNETs) using miRNA signatures. We propose to develop (i) novel, multiplexed and quantitative miRNA FISH with highly specific miRNA probes producing a high signal-to-noise ratio as well as (ii) improved miRNA sequencing by eliminating technical and methodological biases. By combining these great advances in miRNA sequencing and miRNA FISH to quantify and visualize miRNA expression patterns in pNETs, we aim to: 1) discover novel miRNA “signatures” that are specific to pNETs and, therefore, can be used for diagnostic and therapeutic purposes; and 2) detect and quantify circulating pNET-specific miRNAs in blood plasma for an early diagnosis of pNET patients.
The project is based on a long-time collaboration between Dr. Cekan (MultiplexDX) and Dr. Renwick (Queens University, Canada) since they were postdoctoral fellows at Rockefeller University (2009-2013), where they co-developed novel miRNA-based cancer diagnostic technologies.
November 12, 2019 / MultiplexDX Receives Slovak Ministry of Health Grant
The project has received funding from the Ministry of Health of the Slovak Republic in the field of health care for the purposes of research and development (Oncology) under registration number 2019/69 MXDX-1
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.